Literature DB >> 11891945

Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity.

Ronald Schimming1, Dieter Marmé.   

Abstract

BACKGROUND: Increasing evidence suggests that endoglin (CD105) is a new powerful marker of neovascularization in solid malignancies. To explain the rating of CD105 expression in 51 squamous cell carcinoma of the oral cavity (SCCOC) we analyzed CD105 expression in tumor tissue and adjacent normal healthy mucosa.
METHODS: Mean CD105 density was quantitated by counting the number of CD105-immunostained blood vessels. The results were compared with clinical parameters like T and N stage, grading, tumor localization, and specific characteristics of patients by means of statistical analysis.
RESULTS: Endoglin expression in tumor tissue was significantly higher than in normal healthy mucosa (p <.001). With the exception of T3 (n = 2), a higher T stage was correlated with higher endoglin expression. No statistical correlation was found in the analysis of patient's age, gender, and tumor localization.
CONCLUSIONS: Endoglin expression is up-regulated in SCCOC compared with normal healthy oral mucosa. Endoglin may have a significant role in the development of SCCOC and might be relatively more specific than commonly used endothelial markers. Copyright 2002 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891945     DOI: 10.1002/hed.10040

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  14 in total

1.  Expression of NOS and HIF-1alpha in human colorectal carcinoma and implication in tumor angiogenesis.

Authors:  Jian-Xian Yu; Lin Cui; Qi-Yi Zhang; Hua Chen; Ping Ji; Hong-Jun Wei; Hai-Yan Ma
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

2.  Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma.

Authors:  Panayiotis A Kyzas; Dimitrios Stefanou; Anna Batistatou; Niki J Agnantis
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

3.  Expression of Endoglin (CD-105) and Microvessel Density in Oral Dysplasia and Squamous Cell Carcinoma.

Authors:  Maharudrappa Basnaker; Shashikanth Sr; Satish Bnvs
Journal:  J Clin Diagn Res       Date:  2014-09-20

4.  Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver.

Authors:  Joanna-W Ho; Ronnie-T Poon; Chris-K Sun; Wei-Cheng Xue; Sheung-Tat Fan
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

5.  Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma.

Authors:  Panayiotis A Kyzas; Niki J Agnantis; Dimitrios Stefanou
Journal:  Virchows Arch       Date:  2006-04-13       Impact factor: 4.064

6.  Poor prognostic clinicopathologic features correlate with VEGF expression but not with PTEN expression in squamous cell carcinoma of the larynx.

Authors:  Yurdanur Sullu; Seda Gun; Sinan Atmaca; Filiz Karagoz; Bedri Kandemir
Journal:  Diagn Pathol       Date:  2010-06-14       Impact factor: 2.644

Review 7.  Molecular metastases markers in head and neck squamous cell carcinoma: review of the literature.

Authors:  G Cortesina; T Martone
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-12       Impact factor: 2.124

8.  Significance of neo-angiogenesis and immuno-surveillance cells in squamous cell carcinoma of the tongue.

Authors:  Juma O Alkhabuli
Journal:  Libyan J Med       Date:  2007-03-01       Impact factor: 1.657

9.  Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma.

Authors:  Lian-yue Yang; Wei-qun Lu; Geng-wen Huang; Wei Wang
Journal:  BMC Cancer       Date:  2006-05-02       Impact factor: 4.430

10.  Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer.

Authors:  Ester Fonsatti; Michele Maio
Journal:  J Transl Med       Date:  2004-06-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.